Key Highlights

  • SCTX shares rose 3.71% pre-market to $19.67, recovering from a 13.77% decline in Monday's session to a close of $18.97.
  • Scribe Therapeutics priced its IPO at $15.00 per share on July 24, offering 8,580,000 shares for gross proceeds of $128.7 million.
  • The stock remains above its IPO price despite Monday's pullback, having traded as high as $22.75 in its first days on the Nasdaq.
  • Sanofi agreed to purchase 500,000 shares in a concurrent private placement at the IPO price.
  • The company's lead candidate, STX-1150, targeting PCSK9 for LDL cholesterol reduction, has entered a first-in-human trial in Australia.

Shares Recover Slightly After Post-IPO Pullback

Scribe Therapeutics (NASDAQ:SCTX) shares ticked higher in pre-market trading on Tuesday, recovering slightly after falling 13.77 percent in Monday's session, just days after the company's initial public offering on the Nasdaq Global Market. The stock priced at $15.00 per share on July 24, with the company offering 8,580,000 shares for gross proceeds of $128.7 million.

Scribe Therapeutics is an Alameda, California-based clinical-stage biotechnology company developing in vivo CRISPR-based genetic medicines designed to deliver durable, preventive treatment for common cardiometabolic diseases. The company has engineered two proprietary CRISPR platforms: ELXR, an epigenetic silencing technology intended to durably repress disease-causing genes without altering DNA, and XE, a gene-editing system designed for precise, efficient modification.

In a concurrent private placement tied to the offering, Sanofi agreed to purchase 500,000 shares at the IPO price, reinforcing an existing strategic collaboration between the two companies. Despite Monday's pullback, the stock remains above its IPO price, having traded as high as $22.75 in its first days on the exchange.

Lead PCSK9 Program Advances to First-in-Human Trial

Scribe carries a market capitalization of approximately $306.97 million. The company's lead product candidate, STX-1150, uses the ELXR platform to target PCSK9 and aims to provide long-lasting LDL cholesterol reduction without permanent DNA changes, and has entered a first-in-human trial in Australia targeting up to 64 adults with elevated LDL cholesterol. Early non-human primate studies of a prototype showed greater than 50 percent LDL-C reductions sustained for two years after a single dose.

Beyond STX-1150, the company is advancing STX-1200, targeting LPA to address elevated Lp(a), a genetic driver of cardiovascular risk affecting roughly 20 percent of the global population, and STX-1400, targeting APOC3 to reduce triglycerides and pancreatitis risk. Scribe reported collaboration revenue of $51.2 million in 2025, up 87 percent year-over-year, alongside a net loss of $21.8 million, reflecting its pre-commercial stage alongside partnerships with Sanofi and Lilly's Prevail unit.

Conclusion

Scribe Therapeutics' modest pre-market rebound follows a steep decline in its first full trading session after last week's IPO, though the stock remains above its offering price. With its lead STX-1150 program now in first-in-human testing and additional cardiometabolic candidates advancing through preclinical development, the company's early public market performance will likely remain volatile as investors assess the durability of its CRISPR platform data.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.